TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03465644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tailored antithrombotic strategy
Description: Low-dose (60mg) ticagrelor + aspirin for 6months and then clopidogrel alone for 6months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional antithrombotic strategy
Description: Clopidogrel + aspirin for 12months
Study: NCT01472354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leap-c group intervention
Description: 4-week group intervention to help HIV/HCV co-infected patients reframe negative appraisals associated with hCV treatment, increase HCV knowledge, increase skills related to working with health care providers
Study: NCT00863044

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Apnea
Description: Ventilation will be stopped for the duration of the anastomosis as it's done currently. At all other times during the surgery, the ventilatory parameters will be adjusted to maintain a PaCO2 between 40 and 45 mmHg.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High frequency ventilation
Description: The patients will be ventilated using a tidal volume of 1.5 ml per Kg and a respiratory rate of 100 per minute for as long as the surgeon needs to perform the distal anastomosis of the coronaries.
Study: NCT00434980

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Directed Cognitive Adaptation Program
Study: NCT00500565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: On-Q Pain Pump filled with Saline. The On-Q pump will be connected to the catheter to deliver a constant flow of saline for up to 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivicaine
Description: On-Q Pain Pump filled with 0.375% Bupivicaine through two catheters at a total rate of 4 cc/hr over 111 hours. The On-Q pump will be connected to the catheter to deliver a constant flow of Bupivicaine for up to 5 days.
Study: NCT00579969

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Latanoprost
Description: dosage form:eye drops, dosage: One drop in each eye twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Timolol
Description: dosage form:eye drops, dosage: One drop in each eye twice a day
Study: NCT04211285

Intervention type: DIAGNOSTIC_TEST
Intervention: e-GAB
Description: android application for comprehensive geriatric assessment

Intervention type: DIAGNOSTIC_TEST
Intervention: standard physician performed CGA
Description: CGA by an experienced geriatrician blinded to the result of e-GAB
Study: NCT03644498

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT03198091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dun Ye Guan Xin Ning
Description: Dun Ye Guan Xin Ning tablet 320 mg orally every time and 3 times per day for 6 months.
Study: NCT04320212

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: lumber epidural analgesia
Description: the lumber epidural analgesia will be given after induction of general anesthesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae analgesia
Description: the erector spinae analgesia will be given after induction of general anesthesia.
Study: NCT03382197

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nonivasive ventilation
Description: For nebulization associated with NIV, a noninvasive distribution system consisting of a non-toxic orofacial mask connected to the NIV circuit will be used, and the latter will be being fed by a radioaerosol flow generated by a nebulizer coupled to the circuit. This mask will be secured to the patient's face through tabs in order to prevent leakage and to maintain proper pressurizing and better patient adaptation.
Study: NCT01578590

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lean minced meat (beef)
Description: A piece of meat (135 grams, 35 g of protein) or an isonitrogenous-matched milk protein beverage

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lean minced meat (beef)
Description: A piece of meat (135 grams, 35 g of protein) or an isonitrogenous-matched milk protein beverage
Study: NCT00396825

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video-based coping skills training with telephone coaching
Description: Subjects will view the 10 modules of Williams LifeSkills Caregiver Video, do Workbook exercises for each module, and receive telephone coaching to enhance their ability to apply the skills taught in each module to caregiver situations.
Study: NCT02408185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistin 6 million units + 240mg/8h
Description: 240 mg of colistin methanesulfonate (CMS) every 8 hours, 3 million units (MU); 90 mg colistin base activity, (CBA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistin 6 million units + 360mg/12h
Description: 360 mg CMS every 12 hours (4.5 MU; 135 mg CBA)
Study: NCT03878225

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: H.V.M.N. Ketone Ester
Description: The ketone mono ester will be ingested 5 times daily for 3 days (72 hours). Please see above for details.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will be ingested 5 times daily for 3 days (72 hours). Please see above for details.
Study: NCT02398981

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical decision support tool
Study: NCT04313101

Intervention type: OTHER
Intervention: withdrawl of blood samples for thyroid function testing
Description: Blood samples will be withdrawn from patients admitted to the intensive care for more than 7 days to measure Thyroid hormones (Free T3: Tri-iodothyronine and Free T4:thyroxine) and TSH ( Thyroid Stimulating Hormone) using ELISA kits. Reference ranges will be as follows: TSH 0.4-4mU/L, Free T3 2-4.4 mU/L, Free T4 0.8-1.9 mU/L. Patients will be then categorized into one of the following categories~* Euthyroid ( Normal TSH, FT3 and FT4)~* Hyperthyroid (Low TSH) either overt (increased FT3 and /or FT4) or subclinical (normal FT4 and FT3).~* Hypothyroid (Elevated TSH) either overt (Low FT3 and FT4) or subclinical (Normal FT3 and FT4)~* Non-thyroidal illness syndrome : normal or low TSH in addition to low FT3 ± Low FT4 levels.

Intervention type: OTHER
Intervention: withdrawl of blood samples for thyroid function testing
Description: Blood samples will be withdrawn from patients admitted to the intensive care for more than 7 days to measure Thyroid hormones (Free T3: Tri-iodothyronine and Free T4:thyroxine) and TSH ( Thyroid Stimulating Hormone) using ELISA kits. Reference ranges will be as follows: TSH 0.4-4mU/L, Free T3 2-4.4 mU/L, Free T4 0.8-1.9 mU/L. Patients will be then categorized into one of the following categories~* Euthyroid ( Normal TSH, FT3 and FT4)~* Hyperthyroid (Low TSH) either overt (increased FT3 and /or FT4) or subclinical (normal FT4 and FT3).~* Hypothyroid (Elevated TSH) either overt (Low FT3 and FT4) or subclinical (Normal FT3 and FT4)~* Non-thyroidal illness syndrome : normal or low TSH in addition to low FT3 ± Low FT4 levels.
Study: NCT02509247

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Description: Wireless telemonitoring
Study: NCT01628042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron 100 mg
Description: Vibegron tablets, orally, on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron 100 mg
Description: Vibegron tablets, orally, on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron 100 mg
Description: Vibegron tablets, orally, on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vibegron 100 mg
Description: Vibegron tablets, orally, on Day 1
Study: NCT01609725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Subgingival scaling and root planing
Description: Oral hygiene instruction and motivation will be provided altogether with scaling and root planing of all teeth affected by periodontitis under local anesthesia
Study: NCT00437632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive matching placebo capsules to GSK598809 orally with water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive matching placebo capsules to GSK598809 orally with water.
Study: NCT01609725

Intervention type: DEVICE
Group type: OTHER
Intervention: Oral prophylaxis
Description: One session of supraginigval calculus removal
Study: NCT01577004

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid
Description: Subjects will be given four 1 g capsules of fish oil providing 1.4 g/d of EPA and 1.0 g/d of DHA as ethyl esters (Ocean Nutrition, Dartmouth, NS), which is similar to the dose used in previous studies with MCI and AD (20, 21).
Study: NCT02320214

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miami w/ frag Personal lubricant
Study: NCT02067572

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline mouthwash

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salvia mouthwash
Study: NCT03658317

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: renal arterial resistive index
Description: done by dupplex on renal arteries

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: renal arterial resistive index
Description: done by dupplex on renal arteries

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: uric acid level
Description: serum sample for doing the test

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: uric acid level
Description: serum sample for doing the test

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: serum urea and creatinine
Description: serum samples for doing the test
Study: NCT02077244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow up talks
Description: Nurse led follow up talks at the ward and one and two months later.
Study: NCT02927665

Intervention type: DEVICE
Intervention: Reshape Integrated Dual Balloon
Study: NCT04503785

Intervention type: DIAGNOSTIC_TEST
Intervention: Manometry
Description: Transnasal Esophageal manometry and Endoflip Balloon distensibility
Study: NCT03658317

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: serum urea and creatinine
Description: serum samples for doing the test

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 24 hours urinary proteins
Description: urine collected over 24 hours for doing the test

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 24 hours urinary proteins
Description: urine collected over 24 hours for doing the test

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: lipogram
Description: serum sample for doing the test

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: lipogram
Description: serum sample for doing the test

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HbA1c level
Description: serum sample for doing the test

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: HbA1c level
Description: serum sample for doing the test

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: urine analysis
Description: urine sample for doing the test

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: urine analysis
Description: urine sample for doing the test
Study: NCT03118115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of the flap bioimpedance
Description: Measurement of the flap bioimpedance before and after clamping of the artery or the vein. For information: All patients will have the vein and the arterial section simulating venous or arterial thrombosis.
Study: NCT03658317

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: abdominal ultrasonography
Description: done by the ultrasonography device

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: abdominal ultrasonography
Description: done by the ultrasonography device
Study: NCT04142710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine: tablet and possibly tools to perform measurements
Description: Users of telemedicine can answer simple questions about their health condition and/or perform measurements related to their health (e.g., blood pressure, blood sugar, oxygen saturation, weight) via a tablet or a similar device. The results are transferred from the measuring devices to the tablet so that users can easily see them and track their own results over time. The results are transmitted digitally to a follow-up service. The follow-up service contacts the patient in case of signs of deterioration or when measurements lie outside what is normal values for the individual. The follow-up service provides medical support and guidance based on the patient's needs and plan for follow-up, and will, in consultation with the patient, assess whether this should contact their GP/emergency room.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine: tablet and possibly tools to perform measurements
Description: Users of telemedicine can answer simple questions about their health condition and/or perform measurements related to their health (e.g., blood pressure, blood sugar, oxygen saturation, weight) via a tablet or a similar device. The results are transferred from the measuring devices to the tablet so that users can easily see them and track their own results over time. The results are transmitted digitally to a follow-up service. The follow-up service contacts the patient in case of signs of deterioration or when measurements lie outside what is normal values for the individual. The follow-up service provides medical support and guidance based on the patient's needs and plan for follow-up, and will, in consultation with the patient, assess whether this should contact their GP/emergency room.
Study: NCT04134299

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AXA4010
Description: The study will initiate with approximately eight (8) adult subjects (≥18 y/o) with SCD (Cohort 1). Each subject will receive AXA4010 twice a day (BID) for 12 weeks. Safety and tolerability will be monitored, and study procedures will be performed. Analysis of safety, tolerability and laboratory assessments at week 12 would be performed. Based on the 12-week observations from at least three subjects in Cohort 1, subsequent Cohorts 2 and 3 in Part II may be initiated.
Study: NCT03374813

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MimetikOss (bone grafting surgery)
Description: Ridge preservation bone grafting after dental extraction.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bio-Oss (bone grafting surgery)
Description: Ridge preservation bone grafting after dental extraction.
Study: NCT03859752

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TR1801-ADC
Description: Humanized anti-c-Met monoclonal antibody conjugated to a cleavable pyrrolobenzodiazepine toxin
Study: NCT03234933

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobility Tracker
Description: Tracking Patient's movements and calories
Study: NCT01291706

Intervention type: DEVICE
Intervention: Transcranial Doppler
Description: Negative predictive value of transcranial doppler in patients with mild to moderate traumatic brain injury
Study: NCT01308294

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2 vaccine injections in 1 limb
Description: Participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A and MAGE-A3-DP4 peptides with IMP321/LAG-3 ± Montanide. The content of each syringe is injected s.c. in the same limb at about 5 cm distance from each other.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2 vaccine injections in distinct limbs
Description: Participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A and MAGE-A3-DP4 peptides with IMP321/LAG-3 ± Montanide.The content of each syringe is injected s.c. in different limbs.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2 vaccine injections in distinct limbs
Study: NCT02539524

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga bhastrika pranayama breathing exercise
Description: Bhastrika Pranayama is formed by a set of 20 nasal forced and rapid expirations, followed by passive nasal inspirations, followed by 1 alternate nasal breath which always begins through the right nostril, and has a retention between intake and outflow. The set of this breathing exercise is supposed to bring respiratory relief.
Study: NCT01332500

Intervention type: DRUG
Intervention: Sumatriptan/Naproxen combination
Description: Sumatriptan and Naproxen Sodium

Intervention type: DRUG
Intervention: other oral triptans
Description: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan
Study: NCT01567124

Intervention type: DRUG
Group type: OTHER
Intervention: Moxonidine
Description: Participants who are randomly assigned to the moxonidine/experimental group will be treated with moxonidine oral tablets for twelve weeks. Participants will begin their moxonidine treatment at 0.2mg dosage, which will be increased to 0.4mg over the first two weeks.~At the end of the twelve weeks of treatment, participants will be withdrawn from moxonidine over a period of two weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: To examine the effects of moxonidine treatment, a placebo oral tablet will be used for comparison purposes.~The duration and number of placebo tablets participants will be required to take will be the same as the amount required in the moxonidine group.

Intervention type: DRUG
Group type: OTHER
Intervention: Moxonidine
Description: Participants who are randomly assigned to the moxonidine/experimental group will be treated with moxonidine oral tablets for twelve weeks. Participants will begin their moxonidine treatment at 0.2mg dosage, which will be increased to 0.4mg over the first two weeks.~At the end of the twelve weeks of treatment, participants will be withdrawn from moxonidine over a period of two weeks.

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: To examine the effects of moxonidine treatment, a placebo oral tablet will be used for comparison purposes.~The duration and number of placebo tablets participants will be required to take will be the same as the amount required in the moxonidine group.
Study: NCT02539524

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: Pulmonary Rehabilitation Group Intervention consisted of 12-week pulmonary rehabilitation. Two 1 hour sessions a week, consisting of: 30 min of aerobic training followed by resistance exercises for upper and lower limbs.
Study: NCT00005675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral bovine type I collagen
Description: 500 mcg of CI daily for 15 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: CI placebo daily for 15 months
Study: NCT04307901

Intervention type: DEVICE
Intervention: Colon capsule endoscopy
Description: Endoscopy performed using PillCam2 camera capsule for oral ingestion

Intervention type: DEVICE
Intervention: Colon capsule endoscopy
Description: Endoscopy performed using PillCam2 camera capsule for oral ingestion

Intervention type: DEVICE
Intervention: Colon capsule endoscopy
Description: Endoscopy performed using PillCam2 camera capsule for oral ingestion
Study: NCT01120821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec
Description: 400 mg once daily for 12 months
Study: NCT02580240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Hydrocortisone was administered 200 mg/d as a continuous infusion for 6d, then tapered off. Once all vasopressors were discontinued, the taper protocol was initiated (half dose for three days, then quarter dose for three days and then stopped).
Study: NCT01487538

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Videos
Description: Provide information on physical activity, diet, calorie tracking to support weight maintenance in rural women.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action Plans
Description: Online action plans will be used by subjects to set and evaluate physical activity goals

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Discussion Boards
Description: forum to exchange information and experiences

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health behavior tracking
Description: online tracking of weight for both intervention and standard advice group. In addition, the intervention group will also track their calories in and out and their pedometer steps

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health behavior tracking
Description: online tracking of weight for both intervention and standard advice group. In addition, the intervention group will also track their calories in and out and their pedometer steps
Study: NCT02580240

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Vials containing normal saline as placebo were identical to those containing hydrocortisone. Placebo administration procedures were similar.
Study: NCT02279979

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartMate PHP
Description: The HeartMate PHP system is a catheter-based heart pump and console designed to provide hemodynamic left ventricular support for up to 3 days to stabilize patients by maintaining adequate systemic cardiac output.
Study: NCT02324738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine and Dihydroartemisinin-piperaquine
Description: 2 tablets of mefloquine and 3 tablets of dihydroartemisinin-piperaquine single dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wash-out period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mefloquine
Description: 2 tablets of Mefloquine single dose
Study: NCT04447118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: 400 mg, once daily (QD), will be administered with water within 30 minutes after completion of a meal, at approximately the same time each day on a continuous daily dosing schedule, with 21 days as a cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m2, once every 3 weeks (Q3W), will be administered by intravenous infusion over 1 hour, with 21 days as a cycle.